In a patient cohort combining HNSCC and lung SCC using pembrolizumab and nivolumab for PD-1 blockade41, it was observed that tumor samples with a high TLS imprint signature demonstrated a more favorable response to ICB therapy. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.